Jazz Pharmaceuticals (JAZZ) Tops Q2 EPS by 6c, beats revenue
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $245.85 --0%
Financial Fact:
Research and development: 47.8M
Today's EPS Names:
OTLK, EGRX, MOVE, More
Financial Fact:
Research and development: 47.8M
Today's EPS Names:
OTLK, EGRX, MOVE, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q2 EPS of $4.51, $0.06 better than the analyst estimate of $4.45. Revenue for the quarter came in at $957.32 million versus the consensus estimate of $941.99 million.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
- Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
- Prosensa Holding N.V. (RNA) Reports Q2 Loss of $1.18
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
